论文部分内容阅读
目的评价小剂量曲安奈德玻璃体腔内重复注射的安全性。设计前瞻性、非对照干预研究。研究对象31例(31眼),包括黄斑水肿16例、糖尿病性黄斑水肿6例、渗出型老年黄斑变性4例、中央或分支视网膜静脉阻塞3例和非感染性葡萄膜炎2例。方法4mg曲安奈德玻璃体腔内重复注射,在距首次注射分别(2.9±1.1)个月和(4.5±2.5)个月时,分别进行了第2次(31眼)和第3次(9眼)注射,每次注射后监测视力和眼内压等。平均随访(8.4±1.6)个月。主要指标眼压、视力。结果相对于曲安奈德玻璃体腔内单次注射,重复注射并未导致特殊并发症发生。在第1、2、3次注射后分别有23(74.2%)、24(77.4%)和7(77.8%)眼眼压保持正常。3次注射后(每次)眼压的平均值之间比较无显著统计学差异。2眼(6.5%)白内障进展迅速需手术治疗。结论短期随访,小剂量曲安奈德玻璃体腔内重复注射对眼压等无明显影响。
Objective To evaluate the safety of small doses of triamcinolone acetonide in repeated intravitreal injection. Design prospective, uncontrolled intervention study. Thirty-one subjects (31 eyes) included 16 macular edema, 6 diabetic macular edema, 4 exudative age-related macular degeneration, 3 central or branch retinal vein occlusion and 2 non-infectious uveitis. Methods The intravitreous injection of 4mg triamcinolone acetonide was repeated for the second time (31 eyes) and the third time (9 eyes) in the second injection (2.9 ± 1.1) months and (4.5 ± 2.5) months respectively. ) Injection, visual acuity and intraocular pressure after each injection and so on. The average follow-up was (8.4 ± 1.6) months. The main indicators of intraocular pressure, visual acuity. Results Compared to single injection of triamcinolone acetonide vitreous cavity, repeated injections did not result in specific complications. 23 (74.2%), 24 (77.4%) and 7 (77.8%) ocular pressures remained normal after the 1st, 2nd and 3rd injections, respectively. After 3 injections (each time) the average IOP was no significant statistical difference between. 2 eyes (6.5%) cataract rapid progress required surgery. Conclusions Short-term follow-up, small doses of triamcinolone acetonide intravitreal injection repeatedly had no significant effect on intraocular pressure.